Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase III Study of [18F]PSMA-1007 Positron Emission Tomography for the Detection of Prostate Cancer Lesions in Patients With Biochemical Recurrence After Previous Definitive Treatment for Localized Prostate Cancer

NCT04742361 is registered in ClinicalTrials.gov with ABX advanced biochemical compounds GmbH as lead sponsor.

NCT NCT04742361
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04742361 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase III Study of [18F]PSMA-1007 Positron Emission Tomography for the Detection of Prostate Cancer Lesions in Patients With Biochemical Recurrence After Previous Definitive Treatment for Localized Prostate Cancer
Lead sponsor
ABX advanced biochemical compounds GmbH
Phase
Phase 3
Overall status
Completed
Start date
August 27, 2021
Completion date
May 5, 2025
Enrollment
136 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer, prostate cancer recurrent